When the work you do every single day has a crucial impact on the lives of others, every effort, every detail, and every second matters. This shared culture of happiness, passion, and dedication pulses through Cedars-Sinai, and it's just one of the many reasons why we rank as one of the top hospitals by U.S. News & World Report.
Are you ready to be a part of breakthrough research? Apply and join our team!
Dr. Keith Syson Chan's laboratory is seeking a postdoctoral scientist to investigate non-classical mechanisms of therapy resistance, including but not limited to cell death-induced cancer stem cell repopulation [ Nature 517, 209-213(2015) https://rdcu.be/cikEy ], and immunosuppression [ Nature Communications 11: 6299 (2020) https://rdcu.be/cikEQ ]. This project will build on existing mass spectrometry proteomics data to dissect a novel molecular complex in regulating inflammatory cell death mechanisms, and their connections to downstream biologic processes, e.g., immune regulation.
Ideal candidate will be a self-motivated individual enthusiastic to interact with other lab members and the PI, he/she is most welcome to bring new ideas to drive project directions. Expertise in molecular biology of lytic cell death mechanisms, with extensive experience in molecular biology for analyzing protein-protein interaction, molecular complex formation, CRISPR-Cas9 technology for site specific mutations to disrupt protein domain interaction will be highly preferred. Experience in drug screening platforms will be desirable but not required.
KS Chan lab is comprised of an interdisciplinary team https://www.research4cure.org , focusing on cancer research that can translate into early-phase clinical trials or biomarkers to impact patients. We integrate cutting edge single-cell technologies and various study models (e.g., patient-derived xenografts, syngeneic murine models, GEMM) to address key research questions spanning: i) cell death-induced non-classical mechanisms of therapeutic resistance, ii) primary tumor and metastatic niche, and iii) emerging immunologic concepts that impact tumor progression and immune checkpoint response.
Providing healthcare for more than 100 years, Cedars-Sinai has evolved into one of the most dynamic and highly renowned medical centers in the world. Along with caring for patients, Cedars-Sinai is a hub for biomedical research and a training center for future physicians and other healthcare professionals. This attracts exceptional talent to Cedars-Sinai, including world-renowned physician-scientists who seek a place where they can both conduct research and see patients--the ideal formula for discovery and its translation into cures. Our patients benefit from access to doctors at the top of their fields, and our researchers have an ideal community in which to study the impact of healthcare challenges, and reflect that knowledge in their research. The greater Los Angeles area in which Cedars-Sinai resides possesses unparalleled cultural and ethnic diversity which offers outstanding opportunities for translational and clinical research and a dynamic environment for medical education.Although community based, Cedars-Sinai is a major t...eaching hospital affiliated with the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Cedars-Sinai has highly competitive graduate medical education programs in more than 50 specialty and subspecialty areas, a graduate program in biomedical sciences and translational medicine, a clinical scholars program directed towards junior physicians with aspirations to become clinical scientists, and post graduate training opportunities.There are more than 250 full-time faculty members at Cedars-Sinai. The voluntary medical staff, comprised of more than 2,200 specialty board-certified or board-qualified physicians, represent all of the specialties and subspecialties and collaborate with full-time medical staff in the teaching responsibilities of the graduate medical education programs.